Cargando…
Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
Antigen selection and prioritization represent crucial determinants of vaccines’ efficacy. Here, we compare two personalized dendritic cell-based vaccination strategies using whole-tumor lysate or neoantigens. Data in mouse and in cancer patients demonstrate that peptide vaccines using neoantigens p...
Autores principales: | Fritah, Hajer, Graciotti, Michele, Lai-Lai Chiang, Cheryl, Huguenin- Bergenat, Anne-Laure, Petremand, Rémy, Ahmed, Ritaparna, Guillaume, Philippe, Schmidt, Julien, Stevenson, Brian J., Gfeller, David, Harari, Alexandre, Kandalaft, Lana E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025090/ https://www.ncbi.nlm.nih.gov/pubmed/36950115 http://dx.doi.org/10.1016/j.isci.2023.106288 |
Ejemplares similares
-
Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity
por: Bassani-Sternberg, Michal, et al.
Publicado: (2017) -
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy
por: Reimann, Hannah, et al.
Publicado: (2021) -
A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2018) -
Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2019) -
Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics
por: Ade, Catherine M, et al.
Publicado: (2023)